Theravance Given “Neutral” Rating at Zacks (THRX)

Share on StockTwits

Zacks reaffirmed their neutral rating on shares of Theravance (NASDAQ:THRX) in a report issued on Wednesday, AnalystRatingsNetwork reports. They currently have a $29.00 target price on the stock.

Zacks’ analyst wrote, “Theravance’s first quarter 2014 loss of $0.62 per share was wider than the Zacks Consensus Estimate of a loss of $0.53 per share and the year-ago loss of $0.39 per share. The wider year-over-year loss was due to lower revenues and higher costs. We are encouraged by Theravance’s decision to split into two separate publicly traded companies. The procedure will be completed shortly. We are also positive on the approval of COPD drugs Breo Ellipta and Anoro Ellipta in the U.S. The reintroduction of Vibativ in the U.S. is also encouraging. We prefer to remain on the sidelines until more visibility is obtained on commercialization of the drugs. Our target price is $29.00 per share.”

Separately, analysts at Ned Davis Research upgraded shares of Theravance from a sell rating to a neutral rating in a research note on Monday, April 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $32.92.

Shares of Theravance (NASDAQ:THRX) traded up 0.41% during mid-day trading on Wednesday, hitting $27.24. 1,052,782 shares of the company’s stock traded hands. Theravance has a 1-year low of $25.11 and a 1-year high of $42.96. The stock has a 50-day moving average of $28.72 and a 200-day moving average of $34.57. The company’s market cap is $2.993 billion.

Theravance (NASDAQ:THRX) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.09. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $4.52 million. During the same quarter in the previous year, the company posted ($0.39) earnings per share. The company’s revenue for the quarter was down 87.3% on a year-over-year basis. On average, analysts predict that Theravance will post $-1.52 earnings per share for the current fiscal year.

Theravance, Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

To view Zacks’ full report, visit Zacks’ official website.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

TD Securities Increases BCE Price Target to C$49.00
TD Securities Increases BCE Price Target to C$49.00
Bell Aliant PT Raised to C$31.00 at Canaccord Genuity
Bell Aliant PT Raised to C$31.00 at Canaccord Genuity
BMO Capital Markets Increases Altus Group Price Target to C$27.00
BMO Capital Markets Increases Altus Group Price Target to C$27.00
StanCorp Financial Group Rating Reiterated by Credit Suisse
StanCorp Financial Group Rating Reiterated by Credit Suisse
Freeport-McMoRan Receives “Buy” Rating from Jefferies Group
Freeport-McMoRan Receives “Buy” Rating from Jefferies Group
The Boeing Company Rating Reiterated by Sterne Agee
The Boeing Company Rating Reiterated by Sterne Agee


Leave a Reply

 
© 2006-2014 Mideast Time.